Innovative Long-Term Relief with Arthrosamid® at MSK Doctors
Breaking New Ground in Knee Arthritis Care
At MSK Doctors, we pioneered a long-lasting, non-surgical solution for knee osteoarthritis. Backed by our peer-reviewed study, “Polyacrylamide hydrogel injections in knee osteoarthritis: A PROMs-based 24-month cohort study”, provides real-world, two-year evidence of long-term outcomes in everyday clinical settings.
Bringing Evidence to Non-Surgical Knee OA Care
Knee osteoarthritis is a leading cause of pain, reduced mobility, and loss of independence. For years, patients have had limited options: painkillers, steroid injections, and eventually, knee replacement surgery.
MSK Doctors has completed one of the largest two-year follow-up studies on Arthrosamid®, an injectable hydrogel intended to cushion the knee joint. Our published research “Polyacrylamide hydrogel injections in knee osteoarthritis: A PROMs-based 24-month cohort study”, followed patients treated in routine orthopaedic clinics to understand real-world outcomes over time.
- Duration
- Two years
- Participants
- 269 people
- Knees Assessed
- 314 knees
- Setting
- Real-world clinics
Source: Polyacrylamide hydrogel injections in knee osteoarthritis: A PROMs-based 24 month cohort study
What Is Arthrosamid®?
Arthrosamid® is an innovative injectable hydrogel made from cross-linked polyacrylamide and water. Once placed inside the knee joint, it becomes part of the joint lining and acts as a soft, shock-absorbing cushion.
Understanding knee osteoarthritis
Knee osteoarthritis occurs when the cartilage that cushions the joint wears down.
- Persistent pain during movement
- Stiffness after rest
- Swelling or grinding sensations
- Difficulty with stairs, walking, or standing for long periods
Conventional treatments often provide only temporary relief.
Two-Year Clinical Study: Key Findings
We followed 269 people (314 knees) over two years after a single Arthrosamid injection in real-world orthopaedic clinics. Reported outcomes included:
Results highlights
Reported following a single Arthrosamid injection.
Observed in real-world orthopaedic clinics.
Part of the functional improvements reported.
Patients with mild-to-moderate knee wear saw the greatest benefits.
Many patients did not require repeat injections over two years.
The scale and duration make this one of the most comprehensive real-world datasets available. These observations suggest that a single injection may provide long-term benefits for selected patients.